• Shuaihang Chen, Kaihan Wu, Yani Ke, Shanshan Chen, Ran He, Qin Zhang, Chenlu Shen, Qicong Li, Yuting Ruan, Yuqing Zhu, Keying Du, Jie Hu, and Shan Liu.
• The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
• Medicine (Baltimore). 2024 Sep 13; 103 (37): e39613e39613.

BackgroundThe rate of incidence of metabolic dysfunction-related fatty liver disease (MAFLD) has rapidly increased globally in recent years, but early diagnosis is still a challenge. The purpose of this systematic review and meta-analysis is to identify visfatin for early diagnosis of MAFLD.MethodsWe strictly adhered to the relevant requirements of Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The systematic search was conducted in 7 sources (PubMed, Embase, Cochrane Library, CNKI, Wanfang, CBM, and ClinicalTrials.gov) until February 2024. The meta-analysis was performed using Stata 12. Outcomes were expressed in the form of standardized mean difference (SMD) and 95% confidence interval and were analyzed using meta-analysis.ResultsThe results showed that there was no significant difference in circulating visfatin levels between patients with MAFLD and controls (SMD = 0.13 [-0.34, 0.60]). However, the outcomes indicated that the level of circulating visfatin was significantly higher in MAFLD patients in the Middle Eastern subgroup (SMD = 0.45 [0.05, 0.85]) and in the obese patient subgroup (SMD = 1.05 [0.18, 1.92]). No publication bias was detected, and sensitivity analysis confirmed the stability of the outcomes.ConclusionThe serum visfatin levels of MAFLD patients did not differ significantly from those of controls. However, visfatin concentrations in serum were statistically higher within Middle Eastern or obese MAFLD patients compared to controls. There is a need for further research to investigate visfatin's potential as a biomarker for MAFLD.Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.

24 keywords...

hide…